Michael J. Farrell, serving as both Chairman and Chief Executive Officer of ResMed Inc. (NASDAQ:RMD), finalized a transaction to sell company common stock worth approximately $1,090,770 on July 7, 2026. The execution of this sale was governed by a Rule 10b5-1 trading plan, which Farrell originally adopted on October 31, 2024. This structured approach to equity management typically aims to facilitate trading in compliance with securities regulations while mitigating perceptions of timing-based insider activity.
Farrell disposed of 4,991 shares of ResMed common stock during this period. The weighted average price achieved for these shares was $218.5475 per share. The liquidation was not executed as a single block but rather through multiple trades, with execution prices fluctuating between $216.772 and $219.700. This specific transaction contrasts with the current market valuation of the stock, which is trading at $205.84. This current price point reflects a year-to-date decline of roughly 14%. Despite this recent depreciation, analytical models from InvestingPro suggest that the company may remain undervalued at these current levels.
ResMed continues to maintain a substantial market capitalization of $29.69 billion. The company's valuation metrics include a Price-to-Earnings (P/E) ratio of 20. Concurrent with the sale, Farrell engaged in a reciprocal transaction by acquiring 4,991 shares of ResMed common stock. These shares were obtained through the exercise of options priced at $146.34 per share, resulting in a total acquisition cost of approximately $730,382. The options utilized for this acquisition first became exercisable on November 11, 2020, follow a vesting schedule of one-third per year, and are scheduled to expire on November 21, 2026. This acquisition was also integrated into the same Rule 10b5-1 plan.
Following the completion of these reported transactions, Farrell's direct holdings in ResMed common stock stand at 466,223 shares. Furthermore, an additional 2,090 shares are held indirectly through the Lisette and Michael Farrell Family Trust. These figures provide a snapshot of executive equity retention following the complex trading activity.
Corporate strategy at ResMed is undergoing significant shifts. The company recently announced plans to sell MatrixCare to Frazier Healthcare Partners for $490 million in cash. This divestiture represents a notable reduction in ResMed's portfolio, particularly given that the company initially acquired MatrixCare in 2018 for $750 million. In a contrasting strategic move, ResMed is set to acquire Noctrix Health for $340 million, with the deal expected to close on June 1, 2026.
Market reaction and analyst sentiment regarding these developments are divided. Needham has reiterated a Hold rating on ResMed stock following the MatrixCare divestiture announcement. Morgan Stanley has downgraded ResMed to an Equalweight rating from Overweight, citing concerns over margin constraints and modest earnings growth expectations. The firm noted improvements in non-GAAP gross margins but highlighted potential pricing increases and currency movements as ongoing challenges. In contrast, RBC Capital has raised its price target for ResMed to $321, maintaining an Outperform rating. RBC Capital pointed to ResMed's double-digit revenue and earnings growth, which surpassed both its own and consensus estimates.